Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AZD4877 Clear all
Terminated Phase 1 Interventional

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

NCT00471367
View directory record Official record
Conditions
Lymphoma, NHL, Non-Hodgkin Lymphoma
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

NCT00389389
View directory record Official record
Conditions
Neoplasms
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2009 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

NCT00460460
View directory record Official record
Conditions
Lymphoma
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional Results available

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

NCT00486265
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 22, 2026, 2:34 PM EDT